Is Mediwound Ltd (MDWD) Stock About to Get Hot Tuesday?

Mediwound Ltd (MDWD) stock has fallen 3.53% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Mediwound Ltd has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MDWD!

See Full MDWD Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With MDWD Stock Today?

Mediwound Ltd (MDWD) stock has risen 0.45% while the S&P 500 is down -0.83% as of 10:27 AM on Tuesday, Sep 26. MDWD is higher by $0.04 from the previous closing price of $8.97 on volume of 5,929 shares. Over the past year the S&P 500 has gained 17.68% while MDWD is down -7.40%. MDWD lost -$2.40 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Mediwound Ltd click here.

More About Mediwound Ltd

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States. Click Here to get the full Stock Report for Mediwound Ltd stock.